Johnson & Johnson is shaking up oversight of the troubled unit that makes Tylenol and other over-the-counter medicines once again, naming new leadership less than a year after manufacturing problems sparked a revamp. The New Brunswick, N.J., health-products giant is replacing two company group chairmen who held key roles trying to turn around a consumer business racked by recalls and more than $1 billion in lost sales of popular cold, pain and allergy medicines. Patrick Mutchler, who was put in charge of overseeing the McNeil Consumer Healthcare unit last April, is retiring after 35 years at the company, according to people familiar with the departures and an internal company announcement reviewed by The Wall Street Journal. Mr. Mutchler’s duties will be taken over by Roberto Marques, who heads J&J’s consumer businesses in North America.
